5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant plus chemoradiotherapy (CRT) vs placebo plus CRT in a randomized, phase II study

被引：9
|
作者：
Bourhis, J. [1 ]
Le Tourneau, C. [2 ]
Calderon, B. [3 ]
Martin, L. [4 ]
Sire, C. [5 ]
Pointreau, Y. [6 ]
Ramee, J-F. [7 ]
Coutte, A. [8 ]
Boisselier, P. [9 ]
Kaminsky-Forrett, M-C. [10 ]
Delord, J-P. [11 ]
Clatot, F. [12 ]
Sun, X. [13 ,14 ]
Villa, J. [15 ]
Magne, N. [16 ]
Elicin, O. [17 ]
Damstrup, L. [18 ]
Gollmer, K. [19 ]
Crompton, P. [20 ]
Tao, Y. [21 ]
机构：
[1] CHU Vaudois, Dept Radiat Oncol, Lausanne, Switzerland
[2] Inst Curie, Dept Drug Dev & Innovat, Paris, France
[3] Avignon Provence Canc Inst, Oncol Radiotherapy, Avignon, France
[4] William Conqueror Ctr, Radiotherapie, Le Havre, France
[5] South Brittany Hosp Grp, Hop Scorff, Radiotherapie, Lorient, France
[6] Ctr Jean Bernard, Inst Inter Reg Cancerol, Oncol, Radiotherapy, Le Mans, France
[7] CHD Vendee, Onco Hematol Dept, La Roche sur Yon, France
[8] CHU Amiens Picardie, Oncol Radiotherapy Dept, Amiens, France
[9] Montpellier Canc Inst, Oncol Radiotherapie, Montpellier, France
[10] Canc Inst Lorraine Alexis Vautrin, Oncol Med, Nancy, France
[11] IUCT Oncopole, Med Oncol Dept, Inst Claudius Regaud, Toulouse, France
[12] Ctr Henri Becquerel, Serv Oncol Med, Rouen, France
[13] Nord Franche Comte Montbeliard, Dept Radiat Oncol, Montbeliard, France
[14] CHRU Besancon, Dept Radiat Oncol, Montbeliard, France
[15] CHU Grenoble, Pole Cancerol, Dept Radiat, Grenoble, France
[16] Inst Cancerol Lucien Neuwirth, Radiotherapie, St Etienne, France
[17] Univ Bern, Univ Hosp Bern, Inselspital, Dept Radiat Oncol, Bern, Switzerland
[18] Debiopharm Int SA, Clin Res Dept, Lausanne, Switzerland
[19] Debiopharm Int SA, Clin Dev, Lausanne, Switzerland
[20] Debiopharm Int SA, Lausanne, Switzerland
[21] Inst Gustave Roussy, Dept Radiat Oncol, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.08.030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA33
引用
收藏
页码：S1400 / S1400
页数：1
相关论文
共 50 条
  • [1] Phase 2 study of xevinapant plus chemoradiotherapy (CRT) vs placebo plus CRT in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): A post hoc activity analysis by blinded independent review committee evaluation
    Bourhis, Jean
    Eggleton, S. Peter
    Schroeder, Andreas
    Nauwelaerts, Heidi
    Bouisset, Florilene
    Sun, Xu-Shan
    Tao, Yungan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)
    Cohen, E. E.
    Ferris, R. L.
    Psyrri, A.
    Haddad, R.
    Tahara, M.
    Bourhis, J.
    Harrington, K. J.
    Chang, P. M-H.
    Lin, J-C.
    Razaq, M.
    Teixeira, M. M.
    Lovey, J.
    Chamois, J.
    Rueda Dominguez, A.
    Hu, C.
    Dvorkin, M.
    De Beukelaer, S.
    Pavlov, D.
    Thurm, H.
    Lee, N.
    ANNALS OF ONCOLOGY, 2020, 31 : S658 - S658
  • [3] Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design
    Bourhis, Jean
    Burtness, Barbara
    Licitra, Lisa F.
    Nutting, Christopher
    Schoenfeld, Jonathan D.
    Omar, Mokhtar
    Bouisset, Florilene
    Nauwelaerts, Heidi
    Urfer, Yulia
    Zanna, Claudio
    Cohen, Ezra Ew
    FUTURE ONCOLOGY, 2022, 18 (14) : 1669 - 1678
  • [4] Phase IB study of pembrolizumab in combination with chemoradiotherapy (CRT) for locally-advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
    Powell, Steven Francis
    Gitau, Mark Mutuota
    Spanos, William Charles
    Jensen, Ashley Wayne
    Nowak, Ryan Kenneth
    Lohr, Michele
    Puumala, Susan E.
    Ellison, Christie
    Black, Lora Jane
    Cheng, Jonathan D.
    Sacco, Assuntina Gesualda
    Cohen, Ezra E. W.
    Lee, John H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] JAVELIN head and neck 100: A phase 3 trial of avelumab in combination with chemoradiotherapy (CRT) vs CRT for 1st-line treatment of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
    Lee, Nancy Y.
    Ferris, Robert L.
    Beck, J. Thaddeus
    Harrington, Kevin
    Haddad, Robert I.
    Bourhis, Jean
    Tahara, Makoto
    Geraldes, Margarida
    Nuyten, Dimitry S. A.
    Goldberg, Zelanna
    Cohen, Ezra E. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Phase 3 study of Pembrolizumab plus Chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC): KEYNOTE-412
    Machiels, Jean-Pascal
    Yen, Chia-Jui
    Licitra, Lisa
    Rischin, Danny
    Waldron, John
    Burtness, Barbara
    Gregoire, Vincent
    Agarwala, Sanjiv
    Tao, Yun Gan
    Yorio, Jeffrey
    Aksoy, Sercan
    Ikeda, Sadakatsu
    Hong, Ruey-Long
    Ge, Joy Yang
    Brown, Holly
    Bidadi, Behzad
    Siu, Lillian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [7] Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)
    Machiels, J-P.
    Tao, Y.
    Burtness, B.
    Tahara, M.
    Rischin, D.
    Alves, G. V.
    Lima, I. P. F.
    Hughes, B. G. M.
    Pointreau, Y.
    Aksoy, S.
    Laban, S.
    Greil, R.
    Burian, M.
    Hetnal, M.
    Licitra, L. F.
    Swaby, R.
    Zhang, Y.
    Gumuscu, B.
    Bidadi, B.
    Siu, L. L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1399 - S1399
  • [8] Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN)
    Harrington, K. J.
    Berrier, A.
    Robinson, M.
    Remenar, E.
    Housset, M.
    de Mendoza, F. Hurtado
    Compton, N.
    Lau, M.
    Legenne, P.
    Kumar, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Phase I study of concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with unresectable locally advanced squamous cell carcinoma of head and neck (SCCHN).
    Tahara, M
    Minami, H
    Mukai, H
    Kawada, K
    Kawashima, M
    Ogino, T
    Yamazaki, M
    Matsuura, K
    Hayashi, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 518S - 518S
  • [10] Phase II study of dichloroacetate (DCA) in combination with chemoradiation (CRT) for unresected, locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
    Powell, Steven Francis
    Spanos, William Charles
    Black, Lora Jane
    Ellison, Christie
    Miskimins, W. Keith
    Puumala, Susan E.
    Lee, John H.
    Gitau, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345